nach oben

Erschienen in:

02.03.2020 | Preclinical study

Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer

verfasst von: Takahito Masuda, Hiroshi Fujimoto, Ryotaro Teranaka, Masayuki Kuroda, Yasuyuki Aoyagi, Takeshi Nagashima, Takafumi Sangai, Mamoru Takada, Ayako Nakagawa, Yoshitaka Kubota, Koutaro Yokote, Masayuki Ohtsuka

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although recent advances in molecular target therapy have improved the survival of breast cancer patients, high cost and frequent hospital visits result in both societal and individual burden. To reduce these problems, it has been proposed to produce antibodies in vivo. Here, we constructed gene-transduced human ceiling culture-derived proliferative adipocytes secreting anti-HER2 antibody (HER2-ccdPAs) and evaluated their ability to secrete antibody and mediate an anti-tumor effect.

Methods

Plasmid lentivirus was used as a recipient for anti-HER2 antibody cDNA and transduced into human proliferative adipocyte. Secretory antibody expression was evaluated by ELISA and western blot. Specific binding of secretory antibody to HER2 was examined by immunofluorescence analysis. Direct and indirect anti-tumor effects of supernatants from HER2-ccdPAs were evaluated using BT474 (HER2+) and MDA-MB-231 (HER2−) breast cancer cell lines. Additionally, whether adipocyte differentiation affects antibody secretion was investigated using supernatant collected from different cell maturation states.

Results

Anti-HER2 antibody was identified in the supernatant from HER2-ccdPAs and its production increased with the differentiation into mature adipocyte. Antibodies in supernatants from HER2-ccdPAs bound to HER2-positive breast cancer cells similar to trastuzumab. Supernatant from HER2-ccdPAs inhibited the proliferation of BT474 but not MDA-MB-231 cells, and downregulated AKT phosphorylation in BT474 cells compared with controls. Supernatants from HER2-ccdPAs also had an indirect anti-tumor effect on BT474 cells through ADCC. Additionally, Single inoculation of HER2-ccdPAs showed an anti-tumor effect in BT474 xenograft model.

Conclusions

HER2-ccdPAs might be useful for cell-based gene therapy. This system could be a platform for various antibody therapies.

Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444. https://doi.org/10.1016/s0140-6736(11)61625-5 CrossRefPubMed

Anan K, Mitsuyama S, Koga K, Tanabe R, Saimura M, Tanabe Y, Watanabe M, Suehara N, Matsunaga H, Nishihara K, Abe Y, Nakano T, Tamae K, Ono M, Toyoshima S (2010) Disparities in the survival improvement of recurrent breast cancer. Breast Cancer 17(1):48–55. https://doi.org/10.1007/s12282-009-0103-2 CrossRefPubMed

Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100(1):44–52. https://doi.org/10.1002/cncr.11859 CrossRefPubMed

Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Jr., Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C, Herceptin Adjuvant Trial Study T (2017) 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389(10075):1195–1205. https://doi.org/10.1016/S0140-6736(16)32616-2 CrossRef

Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzu D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J (2014) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15(6):640–647. https://doi.org/10.1016/s1470-2045(14)70080-4 CrossRefPubMed

Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28(1):92–98. https://doi.org/10.1200/jco.2008.19.9844 CrossRefPubMed

Ihnenfeld Arcienega I, Imesch P, Fink D, Dedes KJ (2015) Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature. Target Oncol 10(2):297–301. https://doi.org/10.1007/s11523-014-0350-9 CrossRefPubMed

von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Luck HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S (2011) Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3–05 phase III study in HER2-positive breast cancer. Eur J Cancer 47(15):2273–2281. https://doi.org/10.1016/j.ejca.2011.06.021 CrossRef

Kuroda M, Saito Y, Aso M, Yokote K (2018) A novel approach to the treatment of plasma protein deficiency: ex vivo-manipulated adipocytes for sustained secretion of therapeutic proteins. Chem Pharm Bull (Tokyo) 66(3):217–224. https://doi.org/10.1248/cpb.c17-00786 CrossRef

10.

Arafat WO, Gomez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, Barker SD, Mahasreshti PJ, Haisma HJ, Barnes MN, Siegal GP, Alvarez RD, Hemminki A, Nettelbeck DM, Curiel DT (2002) Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Ther 9(4):256–262. https://doi.org/10.1038/sj.gt.3301639 CrossRefPubMed

11.

Jiang M, Shi W, Zhang Q, Wang X, Guo M, Cui Z, Su C, Yang Q, Li Y, Sham J, Liu X, Wu M, Qian Q (2006) Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res 12(20 Pt 1):6179–6185. https://doi.org/10.1158/1078-0432.ccr-06-0746 CrossRefPubMed

12.

Kim H, Danishmalik SN, Hwang H, Sin JI, Oh J, Cho Y, Lee H, Jeong M, Kim SH, Hong HJ (2016) Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2. Cancer Gene Ther 23(10):341–347. https://doi.org/10.1038/cgt.2016.37 CrossRefPubMedPubMedCentral

13.

Kanojia D, Balyasnikova IV, Morshed RA, Frank RT, Yu D, Zhang L, Spencer DA, Kim JW, Han Y, Yu D, Ahmed AU, Aboody KS, Lesniak MS (2015) Neural stem cells secreting anti-her2 antibody improve survival in a preclinical model of her2 overexpressing breast cancer brain metastases. Stem Cells 33(10):2985–2994. https://doi.org/10.1002/stem.2109 CrossRefPubMedPubMedCentral

14.

Wang G, Qiu J, Wang R, Krause A, Boyer JL, Hackett NR, Crystal RG (2010) Persistent expression of biologically active anti-HER2 antibody by AAVrh 10-mediated gene transfer. Cancer Gene Ther 17(8):559–570. https://doi.org/10.1038/cgt.2010.11 CrossRefPubMedPubMedCentral

15.

Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80(1–2):148–158CrossRefPubMed

16.

Ito M, Bujo H, Takahashi K, Arai T, Tanaka I, Saito Y (2005) Implantation of primary cultured adipocytes that secrete insulin modifies blood glucose levels in diabetic mice. Diabetologia 48(8):1614–1620. https://doi.org/10.1007/s00125-005-1825-0 CrossRefPubMed

17.

Kuroda M, Aoyagi Y, Asada S, Bujo H, Tanaka S, Konno S, Tanio M, Ishii I, Machida K, Matsumoto F, Satoh K, Aso M, Saito Y (2011) Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle for enzyme replacement therapy in lecithin: cholesterol acyltransferase deficiency. Open Gene Ther J 4:1–10. https://doi.org/10.2174/1875037001104010001 CrossRef

18.

Sugihara H, Yonemitsu N, Miyabara S, Toda S (1987) Proliferation of unilocular fat cells in the primary culture. J Lipid Res 28(9):1038–1045PubMed

19.

Sugihara H, Yonemitsu N, Miyabara S, Yun K (1986) Primary cultures of unilocular fat cells: characteristics of growth in vitro and changes in differentiation properties. Differentiation 31(1):42–49CrossRefPubMed

20.

Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89(10):4285–4289CrossRefPubMedPubMedCentral

21.

Sanchez-Martin D, Sanz L, Alvarez-Vallina L (2011) Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins. Curr Opin Biotechnol 22(6):924–930. https://doi.org/10.1016/j.copbio.2011.03.001 CrossRefPubMed

22.

Naldini L (2011) Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 12(5):301–315. https://doi.org/10.1038/nrg2985 CrossRefPubMed

23.

Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, Blomqvist L, Hoffstedt J, Naslund E, Britton T, Concha H, Hassan M, Ryden M, Frisen J, Arner P (2008) Dynamics of fat cell turnover in humans. Nature 453(7196):783–787. https://doi.org/10.1038/nature06902 CrossRefPubMed

24.

Billings E Jr, May JW Jr (1989) Historical review and present status of free fat graft autotransplantation in plastic and reconstructive surgery. Plast Reconstr Surg 83(2):368–381CrossRefPubMed

25.

Patrick CW Jr (2001) Tissue engineering strategies for adipose tissue repair. Anat Rec 263(4):361–366CrossRefPubMed

26.

Ailhaud G, Grimaldi P, Negrel R (1992) Cellular and molecular aspects of adipose tissue development. Annu Rev Nutr 12:207–233. https://doi.org/10.1146/annurev.nu.12.070192.001231 CrossRefPubMed

27.

Schaffler A, Buchler C (2007) Concise review: adipose tissue-derived stromal cells–basic and clinical implications for novel cell-based therapies. Stem Cells 25(4):818–827. https://doi.org/10.1634/stemcells.2006-0589 CrossRefPubMed

28.

Aoyagi Y, Kuroda M, Asada S, Tanaka S, Konno S, Tanio M, Aso M, Okamoto Y, Nakayama T, Saito Y, Bujo H (2012) Fibrin glue is a candidate scaffold for long-term therapeutic protein expression in spontaneously differentiated adipocytes in vitro. Exp Cell Res 318(1):8–15. https://doi.org/10.1016/j.yexcr.2011.10.007 CrossRefPubMed

29.

Brockhoff G, Heckel B, Schmidt-Bruecken E, Plander M, Hofstaedter F, Vollmann A, Diermeier S (2007) Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 40(4):488–507. https://doi.org/10.1111/j.1365-2184.2007.00449.x CrossRefPubMedPubMedCentral

30.

Kute TE, Savage L, Stehle JR Jr, Kim-Shapiro JW, Blanks MJ, Wood J, Vaughn JP (2009) Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing. Cancer Immunol Immunother 58(11):1887–1896. https://doi.org/10.1007/s00262-009-0700-0 CrossRefPubMed

31.

Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56(4):361–369. https://doi.org/10.1007/s00280-005-1026-z CrossRefPubMed

Titel: Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer
verfasst von: Takahito Masuda
Hiroshi Fujimoto
Ryotaro Teranaka
Masayuki Kuroda
Yasuyuki Aoyagi
Takeshi Nagashima
Takafumi Sangai
Mamoru Takada
Ayako Nakagawa
Yoshitaka Kubota
Koutaro Yokote
Masayuki Ohtsuka
Publikationsdatum: 02.03.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05581-x

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

HER2-positivity in mucinous cancer might be related to accompanying infiltrating ductal carcinoma histology

Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy

Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients

Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie